Cargando…

Integrative (epi) Genomic Analysis to Predict Response to Androgen-Deprivation Therapy in Prostate Cancer

Therapeutic resistance is a central problem in clinical oncology. We have developed a systematic genome-wide computational methodology to allow prioritization of patients with favorable and poor therapeutic response. Our method, which integrates DNA methylation and mRNA expression data, uncovered a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Panja, Sukanya, Hayati, Sheida, Epsi, Nusrat J., Parrott, James Scott, Mitrofanova, Antonina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013754/ https://www.ncbi.nlm.nih.gov/pubmed/29685789 http://dx.doi.org/10.1016/j.ebiom.2018.04.007

Ejemplares similares

pathCHEMO, a generalizable computational framework uncovers molecular pathways of chemoresistance in lung adenocarcinoma
por: Epsi, Nusrat J., et al.
Publicado: (2019)

Bipotent Progenitors Do Not Require Androgen Receptor for Luminal Specification during Prostate Organogenesis
por: Shibata, Maho, et al.
Publicado: (2020)

Differential requirements of androgen receptor in luminal progenitors during prostate regeneration and tumor initiation
por: Chua, Chee Wai, et al.
Publicado: (2018)

Genome-wide analysis of therapeutic response uncovers molecular pathways governing tamoxifen resistance in ER+ breast cancer
por: Rahem, Sarra M., et al.
Publicado: (2020)

Big Data to Knowledge: Application of Machine Learning to Predictive Modeling of Therapeutic Response in Cancer
por: Panja, Sukanya, et al.
Publicado: (2021)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Integrating diet and exercise into care of prostate cancer patients on androgen deprivation therapy
por: Moyad, Mark A, et al.
Publicado: (2016)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Predictive factor of androgen deprivation therapy for patients with advanced stage prostate cancer
por: Kongseang, Chaiyut, et al.
Publicado: (2017)

Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia
por: Ramakrishnan, Anitha, et al.
Publicado: (2023)

Androgen deprivation therapy as backbone therapy in the management of prostate cancer
por: Merseburger, Axel S, et al.
Publicado: (2016)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia
por: Dillon, Laura W., et al.
Publicado: (2019)

Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
por: Kim, Yejin, et al.
Publicado: (2016)

An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
por: Myklak, Kristene, et al.
Publicado: (2011)

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
por: Chi, Jen‐Tsan, et al.
Publicado: (2020)

Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders
por: Liu, Jui-Ming, et al.
Publicado: (2020)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy
por: Sun, Qi, et al.
Publicado: (2023)

Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy
por: Siddiqui, Zaid A., et al.
Publicado: (2018)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Patients’ Preferences for Androgen Deprivation Therapy in the Treatment of Intermediate-Risk Prostate Cancer
por: De, Brian, et al.
Publicado: (2022)

Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation
por: Brady-Nicholls, Renee, et al.
Publicado: (2020)

Testosterone Recovery after Androgen Deprivation Therapy in Prostate Cancer: Building a Predictive Model
por: Borque-Fernando, Ángel, et al.
Publicado: (2023)

Androgen deprivation therapy for prostate cancer: indications, contraindications and possible consequences
por: Karl, Alexander, et al.
Publicado: (2009)

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
por: Røe, Kathrine, et al.
Publicado: (2012)

Prostate Carcinogenesis with Diabetes and Androgen-Deprivation-Therapy-Related Diabetes: An Update
por: Hara, Noboru
Publicado: (2012)

Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation
por: Lipianskaya, Julia, et al.
Publicado: (2014)

Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer: Prevention and Management
por: Sountoulides, Petros, et al.
Publicado: (2013)

Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer
por: Roayaei, Mahnaz, et al.
Publicado: (2013)

Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer
por: Ali Shah, Syed Imran
Publicado: (2015)

Paradoxical response of prostate cancer skeletal metastases to androgen deprivation therapy
por: Wosnitzer, Brian, et al.
Publicado: (2015)

Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma
por: Lee, Chi-Ho, et al.
Publicado: (2017)

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
por: Merseburger, Axel S., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rqg50b1t1m1qjlb6vlnmir0n4h